Как лечить ВТЭО у онкологических пациентов в остром периоде? Продленное лечение. Роль прямых оральных антикоагулянтов. Результаты исследования HOKUSAI VTE Cancer

Журнал "Атеротромбоз" №2, 2018

DOI: https://doi.org/10.21518/2307-1109-2018-2-28-35

Ю.А. Федоткина, Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр кардиологии» Министерства здравоохранения Российской Федерации

Резюме

Онкологическое заболевание является одним из самых значимых факторов риска развития венозных тромбоэмболических осложнений (ВТЭО). В статье рассматриваются особенности лечения онкологических пациентов с ВТЭО. Рассматриваются вопросы альтернативной антикоагулянтной терапии. Представлены результаты исследования HOKUSAI VTE Cancer – первого завершенного исследования, в котором проводилось сравнение эффективности и безопасности прямого орального антикоагулянта эндоксабана с низкомолекулярным гепарином дальтерапином для лечения ВТЭО у онкологических пациентов.

Yulia A. Fedotkina, Federal State Budgetary Institution «National Medical Research Center of Cardiology» of the Ministry of Health of the Russian Federation

Abstract 

Cancer is one of the most significant risk factors for venous thromboembolic complications (VTEC). The article discusses the features of the treatment of cancer patients with VTEC. The issues of alternative anticoagulant therapy are considered. The article presents the results of HOKUSAI VTE Cancer study, the first completed study to compare the efficacy and safety of a direct oral anticoagulant endoxaban with a low molecular weight heparin dalterapin for the treatment of VTEC in cancer patients.

Загрузить файл статьи в формате PDF

---

Список литературы

1. Levitan N., Dowlati A., Remicks. C., et. al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999; 78: 285-91.
2. Farge D., Khorana A.l. et al. International clinical practice guidelines in the treatment and prophylaxis Vtein patients with cancer. Lancet Oncol. 2016; 17: e452-66.
3. Schulman S., Kearon C., Kakkar A. K., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361: 2342-52.
4. Schulman S., Kakkar A. K., Goldhabers. Z., et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014; 129: 764-72.
5. Bauersachs R., Berkowitz S. D., Brenner B., et al. Oral rivaroxaban for symptomatic venous thromboembolism. N. Engl. J. Med. 2010; 363: 2499-510.
6. Buller H. R., Prins M. H., Lensin A. W., et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N. Engl. J. Med. 2012; 366:1287-97.
7. Prins M. H., Lensing A. W., Bauersachs R., et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and Perandomized studies. Thromb. J. 2013; 11: 21.
8. Agnelli G., Buller H. R., Cohen A., et al. Oral apixaban for the treatment of acute venous thromboembolism. N. Engl. J. Med. 2013; 369: 799-808.
9. Agnelli G., Buller H. R., Cohen A., et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J. Thromb. Haemost. 2015; 13: 2187-91.
10. Buller H. R., Decousus H., Grosso M. A., et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N. Engl. J. Med. 2013; 369: 1406-15.
11. Schulman S., Goldhaber S. Z., Kearon C., Kakkar A. K., Schellong S., Eriksson H., Hantel S., Feuring M., Kreuzer J. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb. Haemost. 2015; 114: 150-157.
12. Raskob G.E., van Es N., Segers A. et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-Vterandomised, double-blind, doubledummy trial. Lancet Haematol. 2016; 3: e379 - e387.
13. Vedovati M. C., et al. Direct oral anticoagulants in patients with Vteand cancer: a systematic review and meta-analysis. Chest. 2015; 147: 475-483.
14. Raskob G.E., van Es N., et al edoxaban for the treatment of cancer-associated venous thromboembolism NEJM. 2017 Dec 12.
15. Young A., et al. Anticoagulation therapy in selected Cancer Patients at Risk of Recurrence of Venous thromboembolism: Results of the select-D Pilot trial. ASH. 2017; Abstract 625.
16. McBane R. II, et al. Apixaban and dalteparin in active malignancy associated venous thromboembolism. the ADAM Vte trial. Thromb. Haemost. 2017; 117. https://doi.org/10.1160/tH17-03-0193.
17. Khorana A. A. Role of direct oral anticoagulants in treatment of cancer-associated venous thromboembolism: guidance the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 2018; 16: 1-4.